Results 161 to 170 of about 184,937 (258)

Alzheimer’s Disease-Associated Molecular Abnormalities in White Matter Glia and Related Pathologies Detected in Unfractionated and O4-Selected Serum Exosomes Using a Liquid Biopsy Approach

Biomedicines
Background/Objectives: White matter degeneration is a significant and early mediator of cognitive impairment in Alzheimer’s disease (AD), yet the critical pathologic features remain poorly understood, under-detected, and therapeutically untargeted ...
Suzanne M. de la Monte, Ming Tong
doaj   +1 more source

Myelin Oligodendrocyte Glycoprotein Antibody Syndrome and Seizures

Annals of Indian Academy of Neurology, 2022
Ayush Agarwal, Pranjal Gupta, Archana Sharma, Anu Gupta, Ajay Garg, Roopa Rajan, Venugopalan Y Vishnu, Rohit Bhatia, Mamta B Singh, Vinay Goyal, M V Padma Srivastava   +10 more
openaire   +3 more sources

Myelin Oligodendrocyte Glycoprotein (MOG)

, 2020
Dr. Lee lectures medical students on myelin oligodendrocytic glycoprotein (MOG)
Andrew G. Lee, MD; Aubrey Lopshire
core  

Biomarkers for myelin oligodendrocyte glycoprotein-associated disease: recent advances and future. [PDF]

Front Immunol
Zheng Q, Wen M, Zheng X, Wen L, Cheng R, Gao Y, Yuan C, Shang P.   +7 more
europepmc   +1 more source

Myelin Oligodendrocyte Glycoprotein Antibodies in Breast Milk in a Lactating Woman With Severe Enterovirus-Associated MOGAD. [PDF]

Neurol Neuroimmunol Neuroinflamm
Kammermeier S, Heck S, Zimmermann H, Engels D, Reindl M, Kümpfel T.   +5 more
europepmc   +1 more source

Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis

, 2019
IC-E4civ-myelin-oligodendrocyte-glycoprotein-antibody-disease; IC-D1bi1-typical-and-atypical-optic-neuritis; IC-D2ci-chiasmal-optic ...
Ilijas Jelcic; James V. M. Hanson; Sebastian Lukas; Konrad P. Weber; Klara Landau; Misha Pless; Markus Reindl; Michael Weller; Roland Martin; Andreas Lutterotti; Sven Schippling
core  

Efficacy of Chronic Immunotherapy for Myelin Oligodendrocyte Glycoprotein-IgG Disease

, 2019
Myelin oligodendrocyte glycoprotein autoantibody (MOG-IgG) is a recently established serum biomarker of demyelinating disease that is associated with recurrent CNS attacks. The optimal treatment to lower the risk of or prevent relapses is unknown.
John Chen; Collin McClelland; Eric Eggenberger; Alfonso Lopez Chiriboga; Victoria Pelak; Heather Moss; Aubrey Gilbert; Michael Lee; Marie Acierno; Muhammad Bhatti; Jiraporn Jitprapaikulsan; Gregory Van Stavern; Divyanshu Dubey; Andrew McKeon; Jeffrey Bennett; Sean Pittock; Eoin Flanagan; Ore-ofe Adesina; Shannon Beres; Dean Cestari; Gena Heidary; Byron Lam; Veeral Shah; John Fraser
core  

Clinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Multicenter Cohort Study. [PDF]

Neurol Neuroimmunol Neuroinflamm
Human M, Gilmartin CGS, Papathanasiou A, Tench CR, Siriratnam P, Rocchi C, Gran B, Hargovan M, The EZ, Varley JA, Huda S, Tanasescu R.   +11 more
europepmc   +1 more source

Do Myelin Oligodendrocyte Glycoprotein Antibodies Represent a Distinct Syndrome?

, 2019
Myelin oligodendrocyte glycoprotein (MOG-IgG) antibodies have been associated with a variety of demyelinating neurologic disorders, including optic neuritis. It remains unclear whether the presence of MOG-IgG represents a distinct syndrome or is simply a
John J. Chen; Clare L. Fraser
core  

Limbic Encephalitis with Anti-myelin Oligodendrocyte Glycoprotein Antibody

Internal Medicine, 2020
Takasone, Ken, Usuda, Maho, Yoshinaga, Tsuneaki, Sekijima, Yoshiki   +3 more
openaire   +3 more sources